Sign In
Buy XLRN
$178.75
+0 (+0%)
At Close: May 27, 2022
Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company
03:30pm, Wednesday, 13'th Oct 2021
NEW YORK--(BUSINESS WIRE)--Holocene Advisors, LP (“Holocene”), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the
Is an Acquisition of Acceleron a Smart Move for Merck?
06:05am, Friday, 08'th Oct 2021
Merck will pick up a promising pipeline candidate with the deal.
New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Acceleron Pharma Inc. (NASDAQ: XLR
With Acceleron Acquisition Merck Stock Is Likely To See A Multiple Revision
10:30am, Monday, 04'th Oct 2021
Merck yesterday announced that it will acquire Acceleron Pharma - a biopharmaceutical company focused on rare diseases - for $11.5 billion funded in cash and debt. Acceleron has multiple potentially b
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acceleron Ph
Activist Investor Thinks Merck Undervalues Acceleron Buy
01:46pm, Friday, 01'st Oct 2021
Hours after Merck & Co Inc's (NYSE: MRK) announcement to acquire Acceleron Pharma Inc (NASDAQ: XLRN), one of Acceleron's activist investors isn't happy with the price tag. Related: Merck Seals
Core PCE Inflation Stays at Record-High in August
12:27pm, Friday, 01'st Oct 2021
Core PCE Inflation Stays at Record-High in August.
Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio
10:09am, Friday, 01'st Oct 2021
Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.
Merck & Co., Inc. (MRK) Merck to Acquire Acceleron Pharma Conference Call (Transcript)
04:22pm, Thursday, 30'th Sep 2021
Merck & Co., Inc. (MRK) Merck to Acquire Acceleron Pharma Conference Call (Transcript)
Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma
03:52pm, Thursday, 30'th Sep 2021
NEW YORK--(BUSINESS WIRE)--Avoro Capital, a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Acceleron Pharma Inc. (NASDAQ: XLRN) to Merck & Co., Inc. for $180.00 per share in
Shareholder Alert: Ademi LLP investigates whether Acceleron Pharma Inc. has obtained a Fair Price in its transaction with Merck
10:17am, Thursday, 30'th Sep 2021
MILWAUKEE, Sept. 30, 2021 /PRNewswire/ -- Ademi LLP is investigating Acceleron (Nasdaq: XLRN), for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.
Merck buying Acceleron Pharma in $11.5B deal
09:41am, Thursday, 30'th Sep 2021
Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs heart.
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
07:34am, Thursday, 30'th Sep 2021
Putting all the speculations at bay, Merck & Co Inc (NYSE: MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ: XLRN) for $180 per share in cash for an approximate total equity value of $11.5
Merck to acquire Acceleron Pharma in $11.5 billion deal
07:16am, Thursday, 30'th Sep 2021
Merck will buy Acceleron Pharma for $180 per share, snapping up Acceleron's late-stage cardiovascular drug in the process. CNBC's Meg Tirrell reports.
